Apricitabine Phase III programme

Avexa AGM 2015


Company Presentation


26th November 2015

Avexa


Forward-looking Statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Avexa to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of pre-clinical proof-of-concept studies, the timing and effects of regulatory actions, the strength of competition and the effectiveness of patent protection.

Additional information regarding risks and uncertainties is

available from Avexa on request.


TALI - exciting new opportunity


TALI Health Acquisition


TALI technology is a breakthrough in the improvement and measuring

of attention in children

An initial focus on developmental delay such as autism.

TALI has been proven to improve attention and school outcomes in a clinical trial

For the first time TALI provides a repeatable measure to replace the

existing, often subjective, measures.

Monash University has developed TALI technology in conjunction with Grey innovation and Torus games


TALI Presentation by Professor Kim Cornish And Jefferson Harcourt
distributed by